TrialScope this year awarded several companies for their clinical trial data transparency efforts as the industry makes strides to engage patients and the larger health care community.
The Pistoia Alliance hopes to facilitate “seamless data integration” between various industry stakeholders, including life sciences companies and CROs, via an open and freely available data format.
Roquette has purchased a majority stake in excipient manufacturer Crest Cellose, in an aim to increase its footprint in India’s generic pharmaceutical market.
The UK Government has granted Arcinova funds to develop its digital manufacturing platform to produce patient-specific medicine at an accelerated rate.
Generics drug portfolios are diversifying, prices are stabilising, and while competition remains intense, the worst of price erosion appears to be over, claims Clarivate Analytics executive.
Elpis Biomed is scaling its proprietary ‘direct cellular reprogramming platform’ – and has its sights set on becoming a global provider of high-quality human cells, with strategic partnerships soon to be announced, says the company’s founder.
This second phase of the two-phase expansion project will increase the company’s bioanalytical capabilities at the site by 50% when the expansion is complete in 2020.
CROs are taking steps to improve study start-up as collaboration with sites and sponsors continues to be a challenge, one which a unified clinical operations model aims to address.
Biorasi plans to scale several aspects of its global CRO business following a PE investment – and while it does not plan to “buy size,” smaller strategic acquisitions are not out of the question, says company executive.
Smithers Avanza’s Bioanalytical Services division is adding 18,500 square feet of laboratory space in New Jersey to support the development of biotherapeutics.
If approved by President Trump, the five-year farm bill – which removes hemp from the federal controlled substance list – could help advance cannabinoid R&D, says Nexien Biopharma.
Histo-Scientific Research Laboratories and Vet Path Services have merged to create one company dedicated to providing histology, pathology, and archiving services to the biopharmaceutical, medical device, and contract research industries.
Merck’s agreement with Cyclica will establish efficiency in its small molecule therapy development with access to Cyclica’s AI protein screening platform.
The expansion collates WuXi AppTec’s technology platform small molecule capabilities, including screening, discovery biology, pharmacology, and process R&D.
By Pamela Tenaerts, executive director, Clinical Trials Transformation Initiative (CTTI)
We entered 2018 with a solid foundation in place for building better, more efficient clinical trials. Throughout the year, progress – particularly in the areas of mobile technologies, real-world evidence, and patient engagement – resulted in new, tangible...
Research involving individuals with schizophrenia can pose unique challenges with recruitment, informed consent, clinical trial design, and the use of placebos.
Cambrex is investing $1m at its High Point, NC-based site, marking the most recent in a series of investments which will see the addition of 1,300 square feet and 15 new employees.
The owners of Synteract, Amulet Capital Partners, have acquired a global health communications and market access group with plans to merge it with Peloton Advantage, which it purchased earlier this year.
M&A is a huge part of the CRO space. Inorganic growth has long been the go-to strategy for any CRO and we’re never surprised to see this month’s latest deal. However, I’d like to challenge the idea that this is always the best way to grow a CRO business.
ICH E6 R2 sparked a paradigm shift, though 2019 will see the clinical trials industry transition from a risk-based monitoring approach to risk-based quality management.
The new year will bring more data than the last 500 decades, information that will be used to improve clinical trial design and shorten drug development timelines, say industry experts.
The industry has a “tremendous opportunity” to build on its progress by further improving operational performance in the face of pricing and patient access challenges.
Throughout 2018 the industry worked to listen more closely to the voice of the patient, though to secure this data, it must navigate currently misunderstood GDPR requirements in the new year.
Potentially increasing costs and dropping returns from investing in innovative medicines and devices will be among the main challenges faced in 2019, says industry analyst.
While several companies touted the potential of AI to disrupt the drug development industry in 2018, what practical applications can the industry expect next year?
Access to medicines across the English Channel could be ‘significantly’ reduced for up to six months, if the UK leaves the EU without a deal, according to MP.
Clinerion and Santa Casa da Misericordia hospital are partnering to bring clinical trial opportunities to patients and diverse data to CROs and sponsors.
